CapWealth Advisors LLC Has $24.23 Million Stake in Johnson & Johnson (NYSE:JNJ)

CapWealth Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,078 shares of the company's stock after purchasing an additional 8,829 shares during the period. Johnson & Johnson accounts for approximately 2.6% of CapWealth Advisors LLC's holdings, making the stock its 12th largest holding. CapWealth Advisors LLC's holdings in Johnson & Johnson were worth $24,226,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. 49 Wealth Management LLC increased its stake in shares of Johnson & Johnson by 133.9% in the 1st quarter. 49 Wealth Management LLC now owns 3,406 shares of the company's stock valued at $565,000 after buying an additional 1,950 shares during the period. Liberty One Investment Management LLC increased its stake in shares of Johnson & Johnson by 4.4% in the 1st quarter. Liberty One Investment Management LLC now owns 194,550 shares of the company's stock valued at $32,264,000 after buying an additional 8,205 shares during the period. Stratos Investment Management LLC increased its stake in shares of Johnson & Johnson by 29.4% in the 1st quarter. Stratos Investment Management LLC now owns 18,854 shares of the company's stock valued at $3,127,000 after buying an additional 4,282 shares during the period. Blackhawk Capital Partners LLC. boosted its position in shares of Johnson & Johnson by 409.5% in the 1st quarter. Blackhawk Capital Partners LLC. now owns 8,524 shares of the company's stock worth $1,414,000 after purchasing an additional 6,851 shares during the last quarter. Finally, May Hill Capital LLC boosted its position in shares of Johnson & Johnson by 12.0% in the 1st quarter. May Hill Capital LLC now owns 2,436 shares of the company's stock worth $404,000 after purchasing an additional 261 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $156.07 on Thursday. The firm has a market cap of $375.52 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The stock's 50-day moving average is $153.67 and its 200-day moving average is $154.27. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.33%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Barclays reduced their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.